Clinical Trials: Vascular
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When AMG 145 is Used in Combination With Statin Therapy In Patients with Clinically Evident Cardiovascular Disease. FOURIER: Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects With Elevated Risk. (IRB# BH-12-254)
- Principal Investor
Gregory Giugliano, MD
This study is for patients aged 40-80 who have had a heart attack or stroke with the past 5 years and
Have one of the following risk factors: type 2 diabetes, age 65-80, heart attack or stroke within past 6 months, 2 or more heart attacks or strokes, or history or symptomatic peripheral arterial disease or amputation in addition to a heart attack or stroke.
Have two or more of the following risk factors: history of non-heart attack related coronary revascularization, residual coronary artery disease, HDL-C < 40 mg/dL for men and < 50 mg/dL for women, hsCRP > 2.0 mg/L, final LDL-C > 130 mg/dL or non-HDL-C > 160 mg/dL, metabolic syndrome.
- Study Site Location
Baystate Heart and Vascular Research, 3300 Main St. Suite 1D, Springfield, MA
Annette Scarnici, RN